Israel’s Neurim Pharmaceuticals is recruiting up to 500 patients with mild Alzheimer's disease, including in Buffalo, for a Phase 2 study of the safety and efficacy of its experimental drug, piromelatine.
The trial, named ReCOGNITION, was designed after pre-clinical studies showed the investigational drug works on the connection between poor sleep and a worsening condition in Alzheimer’s. Initially developed as a sleep aid, piromelatine is now being studied to review its effectiveness in slowing the progression of Alzheimer's through the promotion of better sleep.
Patients in the study will randomly receive different piromelatine oral doses for 26 weeks to determine an effective dose, safety and tolerability, compared to placebo. To enroll, patients must be 60 to 85 years old and suffer from mild dementia associated with Alzheimer’s. In addition, they must have been treated with such acetylcholinesterase inhibitors as Aricept, Exelon and Razadyne, and must have a caregiver who stays with them at least three nights a week and is willing to attend all study visits.
The study is being conducted at 75 sites in the U.S., and includes researchers at the University at Buffalo. For information, visit recognitionstudy.com.
Story topics: Shared